These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 26842686)

  • 81. Iclaprim: a novel dihydrofolate reductase inhibitor for skin and soft tissue infections.
    Morgan A; Cofer C; Stevens DL
    Future Microbiol; 2009 Mar; 4(2):131-44. PubMed ID: 19257839
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Dalbavancin: a review for dermatologists.
    Scheinfeld N
    Dermatol Online J; 2006 May; 12(4):6. PubMed ID: 17083861
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Identification of Patient Characteristics Influencing Setting of Care Decisions for Patients With Acute Bacterial Skin and Skin Structure Infections: Results of a Discrete Choice Experiment.
    Lane S; Johnston K; Sulham KA; Syed I; Pollack CV; Holland T; Nathwani D
    Clin Ther; 2016 Mar; 38(3):531-44; quiz 544.e1-9. PubMed ID: 26874786
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Clinical response at Day 3 of therapy and economic outcomes in hospitalized patients with acute bacterial skin and skin structure infection (ABSSSI).
    Amara S; Adamson RT; Lew I; Huang X
    Curr Med Res Opin; 2013 Jul; 29(7):869-77. PubMed ID: 23659559
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile.
    Henson KE; Levine MT; Wong EA; Levine DP
    Expert Rev Anti Infect Ther; 2015; 13(10):1265-78. PubMed ID: 26165756
    [TBL] [Abstract][Full Text] [Related]  

  • 86. New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.
    Tran TT; Gomez Villegas S; Aitken SL; Butler-Wu SM; Soriano A; Werth BJ; Munita JM
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0261420. PubMed ID: 35475634
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Role or oritavancin and dalbavancin in acute bacterial skin and skin structure infections and other potential indications.
    Bassetti M; Labate L; Vena A; Giacobbe DR
    Curr Opin Infect Dis; 2021 Apr; 34(2):96-108. PubMed ID: 33405480
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Effects of Oritavancin on Coagulation Tests in the Clinical Laboratory.
    Belley A; Robson R; Francis JL; Adcock DM; Tiefenbacher S; Rubino CM; Moeck G; Sylvester D; Dudley MN; Loutit J
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27956417
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Novel developments in the treatment of acute bacterial skin and skin structure infections.
    Jaffa RK; Pillinger KE; Roshdy D; Isip JA; Pasquale TR
    Expert Opin Pharmacother; 2019 Aug; 20(12):1493-1502. PubMed ID: 31145645
    [No Abstract]   [Full Text] [Related]  

  • 90. Impact of human serum albumin on oritavancin in vitro activity against enterococci.
    McKay GA; Beaulieu S; Sarmiento I; Arhin FF; Parr TR; Moeck G
    Antimicrob Agents Chemother; 2009 Jun; 53(6):2687-9. PubMed ID: 19349514
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility.
    Jones RN; Moeck G; Arhin FF; Dudley MN; Rhomberg PR; Mendes RE
    Antimicrob Agents Chemother; 2016 May; 60(5):3174-7. PubMed ID: 26926647
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Successful Treatment of Methicillin Susceptible Staphylococcus aureus Osteomyelitis with Oritavancin.
    Delaportas DJ; Estrada SJ; Darmelio M
    Pharmacotherapy; 2017 Aug; 37(8):e90-e92. PubMed ID: 28543367
    [TBL] [Abstract][Full Text] [Related]  

  • 93. In brief: Oritavancin (Kimyrsa) for skin and skin structure infections.
    Med Lett Drugs Ther; 2021 Aug; 63(1631):e1-e2. PubMed ID: 34544104
    [No Abstract]   [Full Text] [Related]  

  • 94. Omadacycline: A New Tetracycline Antibiotic.
    Dougherty JA; Sucher AJ; Chahine EB; Shihadeh KC
    Ann Pharmacother; 2019 May; 53(5):486-500. PubMed ID: 30917674
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Transitions of care in the management of acute bacterial skin and skin structure infections: a paradigm shift.
    Verastegui JE; Hamada Y; Nicolau DP
    Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1039-45. PubMed ID: 27248789
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.
    Rubino CM; Van Wart SA; Bhavnani SM; Ambrose PG; McCollam JS; Forrest A
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4422-8. PubMed ID: 19635952
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Use of Oritavancin (Novel New Lipoglycopeptide) in the Treatment of Prosthetic Joint Infections (PJI): A Possible Alternative Novel Approach to a Difficult Problem.
    Antony SJ; Cooper LG
    Infect Disord Drug Targets; 2017; 17(2):77-80. PubMed ID: 27829328
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Iclaprim, a dihydrofolate reductase inhibitor antibiotic in Phase III of clinical development: a review of its pharmacology, microbiology and clinical efficacy and safety.
    Huang DB; Dryden M
    Future Microbiol; 2018 Jul; 13():957-969. PubMed ID: 29742926
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.
    Lodise TP; Redell M; Armstrong SO; Sulham KA; Corey GR
    Open Forum Infect Dis; 2017; 4(1):ofw274. PubMed ID: 28480266
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New agents approved for treatment of acute staphylococcal skin infections.
    Tatarkiewicz J; Staniszewska A; Bujalska-Zadrożny M
    Arch Med Sci; 2016 Dec; 12(6):1327-1336. PubMed ID: 27904526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.